BiovaxID given orphan designation for Waldenstrom’s
Biovest International, Inc. (owned by Accentia Biopharmaceuticals) has announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's lead oncology candidate, BiovaxID, for a rare subtype of non-Hodgkin's lymphoma.
BiovaxID is autologous active immunotherapy—a personalized cancer vaccine, in other words—that Biovest has been working on for several years and which has been developed by Dr. Larry Kwak, Chairman of the Department of Lymphoma/Myeloma at the MD Anderson Cancer Center in Houston, Texas.
The subtype is Waldenstrom’s macroglobulinemia, an indolent B-cell non-Hodgkin's lymphoma that is typically treated with single-agent chemotherapy involving alkylating agents (such as chlorambucil), multiagent chemotherapy (involving vincristine, cyclophosphamide, and prednisone, with or without anthtacyclines), or possibly fludarabine.
Biovest's longer term aim is to receive FDA market approval for BiovaxID for the treatment of follicular lymphoma.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
